Abstract:PURPOSE:To compare retrospectively the effects of percutaneous radiofrequency (RF) ablation with those of hepatic resection in the treatment of hepatocellular carcinoma (HCC) measuring 2 cm or smaller. MATERIALS AND METHODS:This study was approved by the institutional ethics committee, and all patients provided written informed consent before treatment. From December 2003 to December 2008, 145 patients with a resectable HCC measuring 2 cm or smaller were studied. Sixty-six patients had a central HCC (located at least 3 cm from the liver capsule). As an initial treatment, 71 patients were treated with percutaneous RF ablation and 74 with surgical resection. Of the patients with central HCC, 37 underwent percutaneous RF ablation and 29 underwent surgical resection. Survival curves were constructed with the Kaplan-Meier method and compared by using the log-rank test. The relative prognostic significance of the variables for predicting overall survival rates was assessed with multivariate Cox proportional hazards regression analysis. Complications were observed clinically when patients were admitted and assessed by telephone interview after patients were discharged. RESULTS:One death was considered to be related to treatment after surgical resection. Major complications occurred significantly more often in the surgical resection group (38 of 74 patients) than in the RF ablation group (14 of 71 patients) (P = .009). The 1-, 3-, and 5-year overall survival rates were 98.5%, 87.7%, and 71.9%, respectively, with RF ablation and 90.5%, 70.9%, and 62.1% with surgical resection (P = .048). The corresponding recurrence-free survival rates were 76.4%, 65.2%, and 59.8% with RF ablation and 75.6%, 56.1%, and 51.3% with surgical resection (P = .548). At subgroup analysis of patients with central HCC, 1-, 3-, and 5-year overall survival rates were 96.6%, 93.0%, and 79.9% with RF ablation and 92.0%, 71.6%, and 61.5% with surgical resection (P = .020). The corresponding recurrence-free survival rates were 86.5%, 74.0%, and 67.0% with RF ablation and 68.0%, 40.0%, and 40.0% with surgical resection (P = .033). For patients with peripheral HCC, 1-, 3-, and 5-year overall survival rates were 97.3%, 83.3%, and 65.1% with RF ablation and 87.8%, 68.4%, and 62.9% with surgical resection (P = .464). The corresponding recurrence-free survival rates were 68.7%, 59.2%, and 54.9% with RF ablation and 82.9%, 66.6%, and 52.9% with surgical resection (P = .351). CONCLUSION:The efficacy and safety of percutaneous RF ablation were better than those of surgical resection in patients with HCC measuring 2 cm or smaller, especially those with central HCC.

Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: A prospective multicenter study

The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population‐based study

US-guided Percutanous Microwave Ablation for Early-Stage Hepatocellular Carcinoma in Elderly Patients is As Effective As in Younger Patients: A 10-Year Experience

Percutaneous Cryoablation Versus Hepatectomy For Hepatocellular Carcinoma Treatment

Overall Survival Rates Become Similar Between Percutaneous Ablation and Hepatic Resection with Increasing Age among Elderly Patients with Early Hepatocellular Carcinoma.

Efficacy and Safety of CT-guided Percutaneous Cryoablation for Hepatocellular Carcinoma at High-risk Sites

Radiofrequency Ablation Versus Open Hepatic Resection for Elderly Patients (> 65 Years) with Very Early or Early Hepatocellular Carcinoma

Percutaneous Radio-Frequency Ablation of Hepatocellular Carcinoma Adjacent to the Gastrointestinal Tract.

[The efficacy and safety of computed tomography-guided percutaneous cryoablation for malignant liver tumors at high-risk sites]

Survival of Patients Receiving Radiofrequency Ablation or Ethanol Injection for Early-Stage Hepatocellular Carcinoma.

Comparison Of Long-Term Effectiveness And Complications Of Radiofrequency Ablation With Hepatectomy For Small Hepatocellular Carcinoma

Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial

Radiofrequency Ablation Of Hepatocellular Carcinoma In Elderly Patients Fitting The Milan Criteria: A Single Centre With 13 Years Experience

Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study.

Efficacy of Hepatic Resection Vs. Radiofrequency Ablation for Patients with Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study with Stratification by Age and Tumor Size

Comparison of procedure-related complications between percutaneous cryoablation and radiofrequency ablation for treating periductal hepatocellular carcinoma

Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery

Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study.

A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.

Long-term Outcomes and Prognostic Analysis of Radiofrequency Ablation for Small Hepatocellular Carcinoma: 10-Year Follow-Up in Chinese Patients

Percutaneous Thermal Ablation of Medium and Large Hepatocellular Carcinoma: Long-term Outcome and Prognostic Factors